

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)



(10) International Publication Number
WO 2025/202368 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) *A61K 38/09* (2006.01)
A61K 9/16 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2025/058418

(22) International Filing Date:

27 March 2025 (27.03.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

24167594.1 28 March 2024 (28.03.2024) EP

(71) Applicant: **DEBIOPHARM INTERNATIONAL SA**
[CH/CH]; Chemin Messidor 5-7, Forum après-demain,
1006 Lausanne (CH).

(72) Inventors: **MORAINE, Victor**; c/o Debiopharm Research
and Manufacturing SA, Rue du Levant 146, 1920 Martigny
(CH). **FAJAS DESCAMPS, Laurence**; c/o Debiopharm
International SA, Chemin Messidor 5-7, Forum après-de-
main, 1006 Lausanne (CH). **MENETREY TACHERON,**
Annick; c/o Debiopharm International SA, Chemin Messi-
dor 5-7, Forum après-demain, 1006 Lausanne (CH). **NICO-**
LAS, Valérie; c/o Debiopharm International SA, Chemin
Messidor 5-7, Forum après-demain, 1006 Lausanne (CH).

(74) Agent: **WEICKMANN & WEICKMANN PARTMBB**;
P.O. Box 860820, 81635 München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: GNRH ANTAGONIST FORMULATION

(57) Abstract: The present invention generally relates to the field of GnRH antagonist formulations. More particularly, the invention relates to pharmaceutical compositions made of microparticles for the slow release of a GnRH antagonist, such as degarelix, medical uses of such pharmaceutical compositions, a kit including such pharmaceutical compositions and methods for the preparation of such pharmaceutical compositions.

WO 2025/202368 A1